Journal
JOURNAL OF THORACIC DISEASE
Volume 10, Issue -, Pages S404-S411Publisher
AME PUBLISHING COMPANY
DOI: 10.21037/jtd.2017.12.93
Keywords
Immunotherapy; surgery; adjuvant; neoadjuvant; non-small cell lung cancer (NSCLC)
Categories
Funding
- National Institutes of Health [P30CA016058, P30CA008748]
Ask authors/readers for more resources
Surgical resection is the mainstay of therapy for patients with resectable and operable early stage non-small cell lung cancer (NSCLC). Surgery alone yields an unacceptably high rate of lung cancer recurrence. The addition of chemotherapy to surgery as adjuvant or neoadjuvant treatment can improve survival rates by roughly 5% at 5 years. Recently, major advances in cancer immunotherapy have led to better outcomes for many patients with lung cancer. Monoclonal antibodies to programmed death 1 and its ligand are now approved for both first and second line treatment patients with metastatic lung cancer. In this review, we will outline the rationale and current research strategies investigating the role of immunotherapy in resectable NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available